Primary Hemophagocytic Lymphohistiocytosis and Hematopoeitic Stem Cell Transplantation in Iran  by Shamsian, BibiShahin et al.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S279eS312S306patients. NM conditioning consisted of ﬂudarabine 90mg/m2
plus 2 Gy TBI, while MA conditioning was cyclophosphamide
120 mg/m2 in combination with 12 Gy TBI or 12.8 mg/kg
busilvex. MA conditioning was given to 122 patients and NM
to 85 patients. Median age at transplant was 39 (range 15-56)
in MA patients and 59 (range 27-73) in NM patients. Donor
source, cytogenetic risk, CMV antigen status recipient/donor,
sex match, Karnofsky score, and body mass index were not
different among MA and NM patients. Disease stages CR1,
CR2, and >CR2/Primary Induction Failure (PIF) were
analyzed separately. Survival of patients with advanced stage
(>CR2/PIF) was short in both groups; 6.1 and 5.2 months in
MA and NM, respectively. Patients in CR1 and CR2 were
analyzed in details. Patient numbers in MA and NM trans-
plants were 60 vs. 62 in CR1 and 50 vs. 17 in CR2. In CR1 and
CR2 MA patients 68% and 48% received bone marrow,
whereas all of the NM patients received peripheral stem
cells, P < .001. Day 100 TRM in MA vs. NM transplants was
8.3% vs. 1.6% in CR1patients and 14% vs. 5.9% in CR2 patients,
which was not signiﬁcantly different. Relapse incidence was
comparable among the MA and NM transplants, both in CR1
and CR2 patients. The cumulative incidence of relapse at 1
year was 18.4% (CI: 5.0-28.2) versus 20.9% (CI: 5.2-31.1) inMA
and NM patients transplanted in CR1, and 14.5% (CI: 5.1-24.5)
versus 11.8% (CI: 0- 27.1) in CR2 patients (n.s.). The 5 year
overall survival (OS) probability in the CR1 patients with MA
conditioning vs NM conditioning was 63.9% (CI:51.4-76.4) vs
64.0% (CI:51.4-76.6), and among CR2 patients 51.2% (CI:36.0-
66.4) vs 64.7 (CI:41.9-87.4), (n.s.). The median survival
follow-up time was 55 months (range: 9-137) among CR 1
patients, and 54 months (range: 7-133) among CR2 patients.
The 3-year cumulative incidence of chronic GVHD in CR1
patients was 52.8% (CI:39.9-65.8) and 41.9% (CI:29.3-54.7) in
MA and NM patients, respectively. In CR2 patients, the inci-
dences were 32.7% (CI:19.0-46.3) and 41.2% (CI:17.8-64.6). In
conclusion, OS, TRM and relapse in NM transplants were
comparable to MA transplants despite a truly NM regimen
and a substantial age difference between groups.Figure 1. OS by Second HCT for Patients with Post-HCT Relapse394
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Background: Relapse is the primary cause of treatment
failure after alloHCT for hematologic malignancies. We
describe the presentation, management, and outcomes of
childrenwith post-HCT relapse, speciﬁcally focusing on post-
HCT minimal residual disease (MRD), to improve monitoring
and intervention strategies.
Design: This was a single institution, retrospective cohort
study of children with relapse or progression of acute
lymphoblastic leukemia (ALL), acute myelogenous leukemia
(AML), mixed phenotypic acute leukemia (MPAL) or myelo-
dysplastic syndrome (MDS) post-alloHCT between January 1,
2003 and December 31, 2010. MRD was deﬁned as disease
detectable by immunophenotypic, cytogenetic or molecular
methods that did not meet classic morphologic criteria for
relapse (deﬁned as 5% disease). Relapse was deﬁned as any
evidence for disease detected after previously negativeresults, includingMRD. Progressive diseasewas deﬁned as an
increase in any measure from baseline results.
Results: 40 of 93 (43%) patients who underwent a ﬁrst
alloHCT experienced relapse, including patients with AML
(n¼18), ALL (n¼16), MPAL (n¼4) andMDS (n¼2). Themedian
time from alloHCT to relapse was 144 days (range 1 month-
58 months). Nine patients with post-HCT MRD as the ﬁrst
evidence for relapse, presented at a median time of 35 days
post-HCT (range 28-182 days), with the majority having
rapid progression of disease. Median survival after relapse
was 123 days (range 4 days-5 years). Estimated 6-month and
1-year post-relapse survival was 30% and 17.5%, respectively.
Five of 40 (12.5%) patients are currently alive with a median
follow-up of 39 months, including 1 patient with active
disease. 1 survivor had MDS and presented with MRD alone.
The remaining 4 (with leukemia) presented with overt
disease between 146 and 411 days post-HCT. 3 of 5 survivors
underwent a second HCT. 11 patients who were able to
undergo a second transplant, experienced a 3-year 27% OS
starting after relapse. (Figure 1). No patients with AML
survived after relapse.
Conclusion: Although pre-emptive treatment of relapse in
the setting of MRD is felt to be ideal, it may not be feasible. In
our study, patients with MRD presented very early post-HCT
at a time when complications can be high and therapeutic
options are limited. Once MRD was detected, disease
progression was rapid limiting the chance to respond to
frontline immunotherapeutic options. Accordingly, there
was no survival advantage for pediatric patients with
leukemia whose relapse was detected as MRD compared to
overt disease. Given the poor outcomes of post-HCT relapse
and limited ability to treat relapse at the stage ofMRD, efforts
should focus on developing effective therapies for relapse
prevention by identifying those at highest risk of relapse as
candidates for novel methods to enhance efﬁcacy of alloHCT.395
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Backkground: Hemophagocytic lymphohistiocytosis (HLH)
is a life-threatening condition characterized by prolonged
fever, hepatosplenomegaly, cytopenia, and hemophagocy-
tosis. Primary HLH is considered fatal unless treated by
hematopoietic stem cell transplantation (HSCT).
Method: Herein we report six Iranian patients as a case
series with primary HLH and their outcome from a single
tertiary-care center Between 2000-2012.
Results: Griscelli syndrome type 2 (GS2) was diagnosed in 3
patients based on clinical, laboratory, and microscopic
features of partial albinism and ﬁnding of RAB27Amutations
in 2 patients tested. Two patients were on the HLH-2004
continuation therapy and waiting for HSCT, but no matched
donor yet: The ﬁrst case is in 2nd remission after 1.5 years;
he had history of relapse in maintenance phase of HLH-2004
protocol which more immunosuppressive treatment was
advised. The second case is in remission after 1 year. Two
other patients died, while waiting for a suitable donor: case 3
had history of recurrent HLH and died after 6 months; and
the case 4 had history of progression to T-cell ALL after 2
years and dead due to relapse of ALL, sepsis and DIC despite
chemotherapy after 3 years. Two patients underwent HSCT;
patient 5 had a HLA-identical sibling donor and patient 6 had
a cord blood-, unrelated, one antigen mismatched donor.
Both patients were treated according to the HLH-2004
treatment protocol and none had active disease at the time of
HSCT. Patient 5 who were diagnosed with GS2 responded
well and remained in remission through 24 months of
follow-up, while another case died because of graft-versus-
host disease and infection on day 136 after HSCT.
Conclusion: HSCT seems to be the only curative treatment
for primary HLH which drastically improve survival of the
patients. Making a deﬁnite diagnosis conﬁrmed by gene
mutation studies is helpful to provide genetic counseling and
prenatal diagnosis and, more important, dictate the need for
HSCT later in the patient's course.
Key words: Hematopoeitic stem cell transplantation;
Hemophagocytic lymphohistiocytosis; Familial HLH; Gris-
celli syndrome type 2396
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Aim: Following Hematopoietic stem cell transplantation
(HSCT), the accurate monitoring of donor-derived cells
prospectively is critical for understanding sustained
engraftment or whether therapeutic intervention is needed,
in turn predicting the success or failure of HSCT.We designed
a highly sensitive, quantitative PCR (qPCR) research assay
speciﬁcally for engraftment monitoring following HSCT in
a research setting. It can accurately detect recipient cells up
to 0.01% while also reducing workﬂow and analysis burdens
as compared to routine STR testings. To enable broader
access to the AlleleSEQR qPCR Chimerism Assay RUO across
more clinical research laboratories, we have assessed
performance of the multiplexed screening assay across ﬁve
different qPCR platforms from four manufacturers.Method: A panel of 34 qPCR research assays to bi-allelic
indels across the genome enables informative marker iden-
tiﬁcation and quantiﬁcation to occur within a few hours and
without the need for capillary electrophoresis. To decrease
our current sample volume requirements, increase
throughput and enable multiple donor screening scenarios
across multiple transplantation centers, we evaluated
a multiplexed assay approach for marker identiﬁcation
utilizing ﬁve different qPCR platforms. The alleles are scored
in relation to ampliﬁcation of an endogenous control assay
and 6-8 samples can be evaluated simultaneously across all
platforms.
Results: Multiplexing the assays to 2-4 assays/well yielded
identical results when compared to single well 34 assays. In
addition, using ﬁve different qPCR platforms i.e. Applied
Biosystems 7500 and ViiA7 Real-Time PCR System, Qiagen
Rotor-Gene Q, Focus 3M Integrated Cycler and Roche
LightCycler 480 System, the described multiplexed qPCR
approach yielded results with 100% concordance in identi-
fying informative markers on six unique Coriell DNA across
platforms.
Conclusions: The results from this multiplexed qPCR
research system for screening of informative markers were
100% concordant to results generated when using the assays
individually. Performance of the multiplex qPCR assays were
independent of the platform providing supportive results for
possible future use in transplant centers.397
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Introduction: Patients with acute myelogenous leukemia
(AML) or non responsive myelodysplastic syndrome (MDS)
who fail to achieve a complete remission, have unfavorable
cytogenetics or are refractory to therapy have a poor prog-
nosis. Allogeneic HSCT is frequently considered a salvage
option for these patients although remissions are short-lived.
New strategies are needed for maintaining remission in this
extremely high risk patient group. We hypothesized hypo-
methylating agents post allogeneic HSCT would enable
patients to remain in complete remission.
Methods: Eleven patients were treated. Patient characteris-
tics: median age, 48 years (range, 18-70 years), PBSC (n¼9) or
bone marrow (n¼2); Diagnoses AML¼ 10, Non- responsive
MDS¼1, CIBMTR disease risk category: High [n¼8], Inter-
mediate [n¼1], Low [n¼2]; 36% of the patients had primary
induction failure, 54% had complex molecular abnormalities
with 18% of the patients having deletion 11q 23 molecular
abnormalities. Donors were unrelated (36%) and related
(64%). All but 1 donor-recipient pairs were fully matched.
Preparative regimen- busulfan based (16mg/kg or equiva-
lent) (82%), TBI  12 Gy (9%) based or reduced-intensity
haplo-identical regimen (9%). The median number of prior
chemotherapy regimens was 2.5 (range, 2-6). Azacitidine
(n¼10) or decitabine (n¼1) was selected at physician
discretion as a planned prophylactic regimen post allogeneic
HSCT engraftment. Initial starting doses were based on
hematological conditions at the time of therapy initiation.
Results: Ten patients received azacitidine subcutaneously
daily for seven days for a median of 5 cycles (range, 1-10
